New Scientist on MSN1d
CAR T-cells enable record-breaking 18-year nerve cancer remission
A person with neuroblastoma, which occurs when developing nerve cells in children turn cancerous, has remained tumour-free ...
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the ...
Hosted on MSN2mon
AmplifyBio and Xcell enter TCR T-cell therapy manufacturing deal
AmplifyBio and Xcell Biosciences have announced a strategic collaboration to advance the manufacturing process for engineered T-cell receptor (TCR) therapies. The alliance will focus on optimising ...
T-knife Therapeutics to Participate in Two Investor Conferences in March
T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) ...
Baylor College of Medicine1d
Long-term survival following CAR T cell therapy to treat neuroblastoma
An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...
Medscape8d
Promise for CAR T-Cell Therapies in Solid Tumors?
CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...
Mena FN6d
T-Cell Receptor Therapy Market Poised For Remarkable Growth By 2032 Delveinsight
Unlike CAR-T cell therapy, which recognizes surface antigens, TCR therapy is engineered to identify intracellular antigens presented by major histocompatibility complex (MHC) molecules ...
Morningstar6d
T-knife Therapeutics to Participate in Two Investor Conferences in March
Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, today announced that members of the company’s management team will ...